Talquetamab for refractory myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests a new drug, talquetamab, for people with myasthenia gravis that has not improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily functioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a diagnosis of myasthenia gravis with muscle weakness that gets worse with activity and improves with rest.
- You have tested positive for anti-AChR antibodies.
- You have moderate to severe symptoms, with significant weakness in muscles other than the eyes.
- Your current treatment has not worked well, or you have had side effects or relapses that make it hard to control the disease.
- Your dose of pyridostigmine (Mestinon) has been stable for at least 1 week before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ripertamab for people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The medicine aims to reduce the immune system's attack on muscles, which may help improve daily activities and quality of life.
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
This study tests a new drug called talquetamab, given as a shot under the skin, for older adults with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if it can help control the cancer with fewer side effects.
This study tests a drug called talquetamab for people with multiple myeloma who have already had a type of immunotherapy called CAR T-cell therapy (ide-cel). The goal is to see if talquetamab can help control the cancer after the CAR T cells have had time to work.
This trial is testing a new medication called blinatumomab for people with difficult-to-treat myasthenia gravis, a condition that causes muscle weakness. The drug aims to help reduce symptoms and improve quality of life for those who haven't improved with standard treatments.
This study looks at how well two newer medicines, teclistamab and talquetamab, work in people with multiple myeloma that has come back or stopped responding to several treatments. If you qualify, you may be able to receive one of these medicines as part of your regular care.
Hear when a new Myasthenia Gravis (MG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.